Covered recipient · General Payments record
RICHARD STEPHEN MORSKI
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$4,144.41
- Reported across 255 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $157.77 | 9 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $31.81 | 2 |
| Abbott Laboratories | $25.81 | 1 |
| Lexicon Pharmaceuticals, Inc. | $21.94 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $19.39 | 1 |
| Merck Sharp & Dohme Corporation | $16.35 | 1 |
| GlaxoSmithKline, LLC. | $14.98 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.97 | 1 |
| Acerta Pharma LLC | $13.52 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (9)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $25.81 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125141123 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.52 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104664981 | CMS |
| GlaxoSmithKline, LLC. | $14.98 | 03/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115973958 | CMS |
| Lexicon Pharmaceuticals, Inc. | $21.94 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1081733837 | CMS |
| Merck Sharp & Dohme LLC | $16.35 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141599469 | CMS |
| Novartis Pharmaceuticals Corporation | $19.39 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087126762 | CMS |
| Novo Nordisk Inc | $17.35 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097325412 | CMS |
| Novo Nordisk Inc | $14.46 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096707857 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.97 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153664494 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.